Wuyuan Lu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7812325/publications.pdf

Version: 2024-02-01

181	10,661	26630 56	40979 93
papers	citations	h-index	g-index

185	185	185	10342
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human Î²-defensin 3. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8880-8885.	7.1	413
2	Î±â€Defensins in human innate immunity. Immunological Reviews, 2012, 245, 84-112.	6.0	359
3	Human Î±-Defensin 6 Promotes Mucosal Innate Immunity Through Self-Assembled Peptide Nanonets. Science, 2012, 337, 477-481.	12.6	337
4	Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4665-4670.	7.1	334
5	Antibacterial Activity and Specificity of the Six Human Î±-Defensins. Antimicrobial Agents and Chemotherapy, 2005, 49, 269-275.	3.2	297
6	Human Î±-defensins block papillomavirus infection. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1516-1521.	7.1	245
7	Human Î±- and Î²-Defensins Block Multiple Steps in Herpes Simplex Virus Infection. Journal of Immunology, 2006, 177, 8658-8666.	0.8	236
8	Antimicrobial Characterization of Human Î²-Defensin 3 Derivatives. Antimicrobial Agents and Chemotherapy, 2003, 47, 2804-2809.	3.2	235
9	Human Î²-Defensins Suppress Human Immunodeficiency Virus Infection: Potential Role in Mucosal Protection. Journal of Virology, 2005, 79, 14318-14329.	3.4	227
10	The Structure of Human Macrophage Inflammatory Protein-3Î±/CCL20. Journal of Biological Chemistry, 2002, 277, 37647-37654.	3.4	210
11	Crystal structures of human Î±â€defensins HNP4, HD5, and HD6. Protein Science, 2006, 15, 2749-2760.	7.6	193
12	D-peptide inhibitors of the p53â€“MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14321-14326.	7.1	191
13	Functional interaction of human neutrophil peptideâ€1 with the cell wall precursor lipid II. FEBS Letters, 2010, 584, 1543-1548.	2.8	180
14	Chiral Protein Supraparticles for Tumor Suppression and Synergistic Immunotherapy: An Enabling Strategy for Bioactive Supramolecular Chirality Construction. Nano Letters, 2020, 20, 5844-5852.	9.1	176
15	Binding of amino acid side-chains to S 1 cavities of serine proteinases 1 1Edited by R. Huber. Journal of Molecular Biology, 1997, 266, 441-461.	4.2	166
16	Dying and Necrotic Neutrophils Are Anti-Inflammatory Secondary to the Release of Î±-Defensins. Journal of Immunology, 2009, 183, 2122-2132.	0.8	141
17	Toward Understanding the Cationicity of Defensins. Journal of Biological Chemistry, 2007, 282, 19653-19665.	3.4	127
18	Induction of group A Streptococcus virulence by a human antimicrobial peptide. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16755-16760.	7.1	119

#	Article	IF	Citations
19	Systematic Mutational Analysis of Peptide Inhibition of the p53â€“MDM2/MDMX Interactions. Journal of Molecular Biology, 2010, 398, 200-213.	4.2	116
20	Defensins: A Double-Edged Sword in Host Immunity. Frontiers in Immunology, 2020, 11, 764.	4.8	114
21	Self-Assembled Peptideâ€“Lanthanide Nanoclusters for Safe Tumor Therapy: Overcoming and Utilizing Biological Barriers to Peptide Drug Delivery. ACS Nano, 2018, 12, 2017-2026.	14.6	110
22	Insight into the Mechanisms of Adenovirus Capsid Disassembly from Studies of Defensin Neutralization. PLoS Pathogens, 2010, 6, e1000959.	4.7	109
23	A Novel Role for Defensins in Intestinal Homeostasis: Regulation of IL-1Î² Secretion. Journal of Immunology, 2007, 179, 1245-1253.	0.8	108
24	Mitochondrial Dysfunction in Obesity-Associated Nonalcoholic Fatty Liver Disease: The Protective Effects of Pomegranate with Its Active Component Punicalagin. Antioxidants and Redox Signaling, 2014, 21, 1557-1570.	5.4	104
25	Through the Looking Glass, Mechanistic Insights from Enantiomeric Human Defensins. Journal of Biological Chemistry, 2009, 284, 29180-29192.	3.4	103
26	A novel method to synthesize cyclic peptides. Tetrahedron Letters, 1998, 39, 3911-3914.	1.4	96
27	Self-Assembling Myristoylated Human Î±-Defensin 5 as a Next-Generation Nanobiotics Potentiates Therapeutic Efficacy in Bacterial Infection. ACS Nano, 2018, 12, 5284-5296.	14.6	96
28	Multivalent Binding of Carbohydrates by the Human Î±-Defensin, HD5. Journal of Immunology, 2009, 183, 480-490.	0.8	91
29	A Leftâ€Handed Solution to Peptide Inhibition of the p53â€“MDM2 Interaction. Angewandte Chemie - International Edition, 2010, 49, 3649-3652.	13.8	91
30	Defensins in innate immunity. Current Opinion in Hematology, 2014, 21, 37-42.	2.5	91
31	Probing Intermolecular Main Chain Hydrogen Bonding in Serine Proteinaseâ^'Protein Inhibitor Complexes:â€‰ Chemical Synthesis of Backbone-Engineered Turkey Ovomucoid Third Domain. Biochemistry, 1997, 36, 673-679.	2.5	88
32	Neisseria gonorrhoeae-Induced Human Defensins 5 and 6 Increase HIV Infectivity: Role in Enhanced Transmission. Journal of Immunology, 2008, 180, 6176-6185.	0.8	87
33	Human neutrophil Î±â€defensin 4 inhibits HIVâ€1 infection in vitro. FEBS Letters, 2005, 579, 162-166.	2.8	86
34	Retrocyclins Kill Bacilli and Germinating Spores of Bacillus anthracis and Inactivate Anthrax Lethal Toxin. Journal of Biological Chemistry, 2006, 281, 32755-32764.	3.4	79
35	Differential Roles of Chemokines CCL2 and CCL7 in Monocytosis and Leukocyte Migration during West Nile Virus Infection. Journal of Immunology, 2015, 195, 4306-4318.	0.8	78
36	Water molecules participate in proteinaseâ€inhibitor interactions: Crystal structures of Leu¹⁸, Ala¹⁸, and Gly¹⁸ variants of turkey ovomucoid inhibitor third domain complexed with Streptomyces griseus proteinase B. Protein Science, 1995, 4, 1985-1997.	7.6	77

#	Article	IF	Citations
37	Cervicovaginal Secretions Contribute to Innate Resistance to Herpes Simplex Virus Infection. Journal of Infectious Diseases, 2005, 192, 1731-1740.	4.0	76
38	Structureâ€dependent functional properties of human defensin 5. FEBS Letters, 2007, 581, 515-520.	2.8	76
39	The Membrane-Bound Structure and Topology of a Human Î±-Defensin Indicate a Dimer Pore Mechanism for Membrane Disruption. Biochemistry, 2010, 49, 9770-9782.	2.5	76
40	Multifaceted Mechanisms of HIV-1 Entry Inhibition by Human Î±-Defensin. Journal of Biological Chemistry, 2012, 287, 28821-28838.	3.4	74
41	Reconstruction of the Conserved Î²-Bulge in Mammalian Defensins Using d-Amino Acids. Journal of Biological Chemistry, 2005, 280, 32921-32929.	3.4	73
42	Apamin as a Template for Structureâ€Based Rational Design of Potent Peptide Activators of p53. Angewandte Chemie - International Edition, 2009, 48, 8712-8715.	13.8	72
43	An Ultrahigh Affinity <scp>d</scp>-Peptide Antagonist Of MDM2. Journal of Medicinal Chemistry, 2012, 55, 6237-6241.	6.4	71
44	Human Defensins Facilitate Local Unfolding of Thermodynamically Unstable Regions of Bacterial Protein Toxins. Immunity, 2014, 41, 709-721.	14.3	71
45	Inhibition of pathologic retinal neovascularization by Â-defensins. Blood, 2005, 106, 3831-3838.	1.4	70
46	Turning a Scorpion Toxin into an Antitumor Miniprotein. Journal of the American Chemical Society, 2008, 130, 13546-13548.	13.7	69
47	Defensins enable macrophages to inhibit the intracellular proliferation of Listeria monocytogenes. Cellular Microbiology, 2011, 13, 635-651.	2.1	68
48	Functional Determinants of Human Enteric Î±-Defensin HD5. Journal of Biological Chemistry, 2012, 287, 21615-21627.	3.4	68
49	Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4350-4355.	7.1	66
50	Binding of amino acid side chains to preformed cavities: Interaction of serine proteinases with turkey ovomucoid third domains with coded and noncoded P₁ residues. Protein Science, 1993, 2, 786-799.	7.6	65
51	Productive Folding of Human Neutrophil Î±-Defensins in Vitro without the Pro-peptide. Journal of the American Chemical Society, 2003, 125, 2402-2403.	13.7	65
52	Human Defensins: Synthesis and Structural Properties. Current Pharmaceutical Design, 2007, 13, 3096-3118.	1.9	65
53	Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry. Journal of Biological Chemistry, 2010, 285, 19572-19581.	3.4	65
54	A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity. Theranostics, 2021, 11, 6833-6846.	10.0	65

#	Article	IF	Citations
55	Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology, 2011, 8, 45.	2.0	61
56	Critical Determinants of Human Î±-Defensin 5 Activity against Non-enveloped Viruses. Journal of Biological Chemistry, 2012, 287, 24554-24562.	3.4	61
57	Biosynthetic phage display: a novel protein engineering tool combining chemical and genetic diversity. Chemistry and Biology, 2000, 7, 263-274.	6.0	60
58	Selfâ€Assembly of Therapeutic Peptide into Stimuliâ€Responsive Clustered Nanohybrids for Cancerâ€Targeted Therapy. Advanced Functional Materials, 2019, 29, 1807736.	14.9	59
59	Comparative Total Syntheses of Turkey Ovomucoid Third Domain by Both Stepwise Solid Phase Peptide Synthesis and Native Chemical Ligation. Journal of the American Chemical Society, 1996, 118, 8518-8523.	13.7	58
60	Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14331-14336.	7.1	58
61	Selective arginines are important for the antibacterial activity and host cell interaction of human Î±â€defensin 5. FEBS Letters, 2009, 583, 2507-2512.	2.8	57
62	Stapled RGD Peptide Enables Glioma-Targeted Drug Delivery by Overcoming Multiple Barriers. ACS Applied Materials & Interfaces, 2017, 9, 17745-17756.	8.0	57
63	Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy. Biomaterials, 2018, 167, 132-142.	11.4	56
64	Human Î±-Defensins Inhibit Hemolysis Mediated by Cholesterol-Dependent Cytolysins. Infection and Immunity, 2009, 77, 4028-4040.	2.2	54
65	Trp-26 Imparts Functional Versatility to Human Î±-Defensin HNP1. Journal of Biological Chemistry, 2010, 285, 16275-16285.	3.4	54
66	Binding characteristics of the Lactobacillus brevis ATCC 8287 surface layer to extracellular matrix proteins. FEMS Microbiology Letters, 2006, 260, 210-215.	1.8	52
67	The Conserved Salt Bridge in Human Î±-Defensin 5 Is Required for Its Precursor Processing and Proteolytic Stability. Journal of Biological Chemistry, 2008, 283, 21509-21518.	3.4	52
68	A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. Journal of Controlled Release, 2015, 218, 29-35.	9.9	51
69	Turning Defense into Offense: Defensin Mimetics as Novel Antibiotics Targeting Lipid II. PLoS Pathogens, 2013, 9, e1003732.	4.7	50
70	Interferon-Induced Transmembrane Protein 3 Blocks Fusion of Diverse Enveloped Viruses by Altering Mechanical Properties of Cell Membranes. ACS Nano, 2021, 15, 8155-8170.	14.6	50
71	A novel conotoxin from Conus striatus, Î¼-SIIIA, selectively blocking rat tetrodotoxin-resistant sodium channels. Toxicon, 2006, 47, 122-132.	1.6	49
72	Predicting the reactivity of proteins from their sequence alone: Kazal family of protein inhibitors of serine proteinases. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1410-1415.	7.1	49

#	Article	IF	Citations
73	Why Is the Arg5-Glu13 Salt Bridge Conserved in Mammalian Î±-Defensins?. Journal of Biological Chemistry, 2005, 280, 43039-43047.	3.4	48
74	Defensins: The natural peptide antibiotic. Advanced Drug Delivery Reviews, 2021, 179, 114008.	13.7	48
75	Human Enteric Î±-Defensin 5 Promotes Shigella Infection by Enhancing Bacterial Adhesion and Invasion. Immunity, 2018, 48, 1233-1244.e6.	14.3	47
76	Amino acid sequences of ovomucoid third domain from 25 additional species of birds. The Protein Journal, 1990, 9, 715-725.	1.1	45
77	CCR6 ligands inhibit HIV by inducing APOBEC3G. Blood, 2010, 115, 1564-1571.	1.4	45
78	Sometimes It Takes Two to Tango. Journal of Biological Chemistry, 2012, 287, 8944-8953.	3.4	45
79	Mirror image proteins. Current Opinion in Chemical Biology, 2014, 22, 56-61.	6.1	45
80	Toxins and derivatives in molecular pharmaceutics: Drug delivery and targeted therapy. Advanced Drug Delivery Reviews, 2015, 90, 101-118.	13.7	45
81	Arg15-Lys17-Arg18 turkey ovomucoid third domain inhibits human furin. Journal of Biological Chemistry, 1993, 268, 14583-5.	3.4	45
82	Defensins Potentiate a Neutralizing Antibody Response to Enteric Viral Infection. PLoS Pathogens, 2016, 12, e1005474.	4.7	44
83	Total chemical synthesis of N-myristoylated HIV-1 matrix protein p17: Structural and mechanistic implications of p17 myristoylation. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11587-11592.	7.1	43
84	Resonance Assignment and Three-Dimensional Structure Determination of a Human Î±-Defensin, HNP-1, by Solid-State NMR. Journal of Molecular Biology, 2010, 397, 408-422.	4.2	43
85	Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53â€“MDM2 interaction. Bioorganic and Medicinal Chemistry, 2013, 21, 4045-4050.	3.0	43
86	Dithiocarbamate-inspired side chain stapling chemistry for peptide drug design. Chemical Science, 2019, 10, 1522-1530.	7.4	43
87	Structural and Functional Analysis of the Pro-Domain of Human Cathelicidin, LL-37. Biochemistry, 2013, 52, 1547-1558.	2.5	42
88	Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy. ACS Nano, 2018, 12, 11664-11677.	14.6	40
89	N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant. Journal of Leukocyte Biology, 2006, 80, 1395-1404.	3.3	38
90	Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of Î² chemokines and RNases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5411-5416.	7.1	38

#	Article	IF	Citations
91	Delineation of Interfaces on Human Alpha-Defensins Critical for Human Adenovirus and Human Papillomavirus Inhibition. PLoS Pathogens, 2014, 10, e1004360.	4.7	38
92	BmBKTx1, a Novel Ca2+-activated K+ Channel Blocker Purified from the Asian Scorpion Buthus martensi Karsch. Journal of Biological Chemistry, 2004, 279, 34562-34569.	3.4	37
93	Curcumin analog 1, 5-bis (2-trifluoromethylphenyl)-1, 4-pentadien-3-one exhibits enhanced ability on Nrf2 activation and protection against acrolein-induced ARPE-19 cell toxicity. Toxicology and Applied Pharmacology, 2013, 272, 726-735.	2.8	37
94	Deciphering the Role of the Electrostatic Interactions Involving Gly70 in Eglin C by Total Chemical Protein Synthesis. Biochemistry, 2000, 39, 3575-3584.	2.5	35
95	Interrogation of MDM2 Phosphorylation in p53 Activation Using Native Chemical Ligation: The Functional Role of Ser17 Phosphorylation in MDM2 Reexamined. Journal of the American Chemical Society, 2012, 134, 6855-6864.	13.7	35
96	Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch. Chemistry of Materials, 2018, 30, 7034-7046.	6.7	35
97	Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. Viruses, 2021, 13, 1246.	3.3	35
98	Coordination of MYH DNA glycosylase and APE1 endonuclease activities via physical interactions. DNA Repair, 2013, 12, 1043-1052.	2.8	33
99	Pro-inflammatory and pro-apoptotic properties of Human Defensin 5. Biochemical and Biophysical Research Communications, 2013, 436, 557-562.	2.1	33
100	A lanthanide-peptide-derived bacterium-like nanotheranostic with high tumor-targeting, -imaging and -killing properties. Biomaterials, 2019, 206, 13-24.	11.4	33
101	Preclinical Evaluation of Synthetic â^'2 RANTES as a Candidate Vaginal Microbicide To Target CCR5. Antimicrobial Agents and Chemotherapy, 2006, 50, 1497-1509.	3.2	31
102	Impact of Pro Segments on the Folding and Function of Human Neutrophil Î±-Defensins. Journal of Molecular Biology, 2007, 368, 537-549.	4.2	31
103	Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240. Scientific Reports, 2016, 6, 36685.	3.3	31
104	The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis. Cancer Research, 2017, 77, 14-26.	0.9	31
105	Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5. Journal of Leukocyte Biology, 2005, 78, 442-452.	3.3	30
106	Invariant Gly Residue Is Important for Î±-Defensin Folding, Dimerization, and Function. Journal of Biological Chemistry, 2012, 287, 18900-18912.	3.4	30
107	IFN-Îµ protects primary macrophages against HIV infection. JCI Insight, 2016, 1, e88255.	5.0	30
108	A tetrameric protein scaffold as a nano-carrier of antitumor peptides for cancer therapy. Biomaterials, 2019, 204, 1-12.	11.4	30

#	Article	IF	Citations
109	CCL7 Is a Negative Regulator of Cutaneous Inflammation Following Leishmania major Infection. Frontiers in Immunology, 2019, 9, 3063.	4.8	29
110	Single, Double and Quadruple Alanine Substitutions at Oligomeric Interfaces Identify Hydrophobicity as the Key Determinant of Human Neutrophil Alpha Defensin HNP1 Function. PLoS ONE, 2013, 8, e78937.	2.5	29
111	Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics. Journal of Controlled Release, 2020, 325, 293-303.	9.9	28
112	The Antimicrobial Peptide Human Beta-Defensin 2 Inhibits Biofilm Production of Pseudomonas aeruginosa Without Compromising Metabolic Activity. Frontiers in Immunology, 2020, 11, 805.	4.8	28
113	Probing intermolecular backbone H-bonding in serine proteinase-protein inhibitor complexes. Chemistry and Biology, 1999, 6, 419-427.	6.0	27
114	Effects of the terminal charges in human neutrophil Î±-defensin 2 on its bactericidal and membrane activity. Peptides, 2005, 26, 2377-2383.	2.4	26
115	Contribution of peptide bonds to inhibitor-protease binding: crystal structures of the turkey ovomucoid third domain backbone variants OMTKY3-Pro18I and OMTKY3-Î¨[COO]-Leu18I in complex with Streptomyces griseus proteinase B (SGPB) and the structure of the free inhibitor, OMTKY3-Î¨[CH2NH2+]-Asp19I. Journal of Molecular Biology, 2001, 305, 839-849.	4.2	25
116	Chemically synthesized human survivin does not inhibit caspaseâ€3. Protein Science, 2008, 17, 1624-1629.	7.6	25
117	Mucosal Human Defensins 5 and 6 Antagonize the Anti-HIV Activity of Candidate Polyanion Microbicides. Journal of Innate Immunity, 2011, 3, 208-212.	3.8	24
118	Total Chemical Synthesis of Human Psoriasin by Native Chemical Ligationâ€. Biochemistry, 2005, 44, 14688-14694.	2.5	23
119	Molecular and functional characterization of bovine Î²-defensin-1. Veterinary Immunology and Immunopathology, 2006, 113, 181-190.	1.2	23
120	Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity. Immunobiology, 2017, 222, 807-813.	1.9	23
121	Human Beta Defensin 2 Selectively Inhibits HIV-1 in Highly Permissive CCR6+CD4+ T Cells. Viruses, 2017, 9, 111.	3.3	23
122	Total chemical synthesis of bovine pancreatic trypsin inhibitor by native chemical ligation. FEBS Letters, 1998, 429, 31-35.	2.8	22
123	Molecular Determinants for the Interaction of Human Neutrophil Î± Defensin 1 with its Propeptide. Journal of Molecular Biology, 2008, 381, 1281-1291.	4.2	22
124	Integrin Î±4Î²7 Expression Increases HIV Susceptibility in Activated Cervical CD4+ T Cells by an HIV Attachment-Independent Mechanism. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 509-518.	2.1	22
125	A Hierarchical Peptideâ€“Lanthanide Framework To Accurately Redress Intracellular Carcinogenic Proteinâ€“Protein Interaction. Nano Letters, 2019, 19, 7918-7926.	9.1	22
126	Tanshinones: First-in-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle of Pseudomonas aeruginosa for Antibiotic Therapy. ACS Central Science, 2019, 5, 1278-1288.	11.3	21

#	Article	IF	Citations
127	Solution Structure of BmBKTx1, a New BKCa1Channel Blocker from the Chinese ScorpionButhus martensiKarschâ€,â€¡. Biochemistry, 2004, 43, 3764-3771.	2.5	20
128	Human Defensins: Turning Defense into Offense?. Infectious Disorders - Drug Targets, 2007, 7, 67-70.	0.8	20
129	Peptide Activators of the p53 Tumor Suppressor. Current Pharmaceutical Design, 2011, 17, 603-609.	1.9	20
130	Sub-Inhibitory Concentrations of Human Î±-defensin Potentiate Neutralizing Antibodies against HIV-1 gp41 Pre-Hairpin Intermediates in the Presence of Serum. PLoS Pathogens, 2013, 9, e1003431.	4.7	20
131	Identification of amino acid residues critical for the B cell growth-promoting activity of HIV-1 matrix protein p17 variants. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 13-24.	2.4	20
132	Inhibition of SARS-CoV-2 Infection by Human Defensin HNP1 and Retrocyclin RC-101. Journal of Molecular Biology, 2022, 434, 167225.	4.2	19
133	The metastatic microenvironment: Lungâ€derived factors control the viability of neuroblastoma lung metastasis. International Journal of Cancer, 2013, 133, 2296-2306.	5.1	18
134	The Î¸-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection. Journal of Leukocyte Biology, 2017, 102, 1103-1113.	3.3	18
135	Human Enteric Defensin 5 PromotesShigellaInfection of Macrophages. Infection and Immunity, 2019, 88, .	2.2	18
136	Crystal structure of a cyclic form of bovine pancreatic trypsin inhibitor. FEBS Letters, 2001, 509, 90-94.	2.8	17
137	Structures of thymus and activation-regulated chemokine (TARC). Acta Crystallographica Section D: Biological Crystallography, 2003, 59, 1165-1173.	2.5	17
138	Nanodefensin-encased hydrogel with dual bactericidal and pro-regenerative functions for advanced wound therapy. Theranostics, 2021, 11, 3642-3660.	10.0	17
139	Deleterious effects of Î²â€branched residues in the S₁specificity pocket ofStreptomyces griseusproteinase B (SGPB): Crystal structures of the turkey ovomucoid third domain variants Ile18I, Val18I, Thr18I, and Ser18I in complex with SGPB. Protein Science, 2000, 9, 83-94.	7.6	16
140	Topology of the disulfide bonds in the antiviral lectin scytovirin. Protein Science, 2010, 19, 1649-1661.	7.6	16
141	Human defensin-inspired discovery of peptidomimetic antibiotics. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117283119.	7.1	16
142	Rattusin, an Intestinal Î±-Defensin-Related Peptide in Rats with a Unique Cysteine Spacing Pattern and Salt-Insensitive Antibacterial Activities. Antimicrobial Agents and Chemotherapy, 2013, 57, 1823-1831.	3.2	15
143	Anti-HIV Activity of Human Defensin 5 in Primary CD4+ T Cells under Serum-Deprived Conditions Is a Consequence of Defensin-Mediated Cytotoxicity. PLoS ONE, 2013, 8, e76038.	2.5	15
144	A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17. Scientific Reports, 2017, 7, 6555.	3.3	15

#	Article	IF	Citations
145	Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression. Acta Pharmaceutica Sinica B, 2021, 11, 2655-2669.	12.0	15
146	Functional intersection of Human Defensin 5 with the TNF receptor pathway. FEBS Letters, 2014, 588, 1906-1912.	2.8	14
147	Potential role of autophagy in the bactericidal activity of human PMNs forBacillus anthracis. Pathogens and Disease, 2015, 73, ftv080.	2.0	14
148	Human Alpha-Defensin HNP1 Increases HIV Traversal of the Epithelial Barrier: A Potential Role in STI-Mediated Enhancement of HIV Transmission. Viral Immunology, 2015, 28, 609-615.	1.3	14
149	Retrocyclins neutralize bacterial toxins by potentiating their unfolding. Biochemical Journal, 2015, 467, 311-320.	3.7	14
150	Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17. Pathogens and Disease, 2015, 73, ftv062.	2.0	14
151	Functional synergism of Human Defensin 5 and Human Defensin 6. Biochemical and Biophysical Research Communications, 2015, 467, 967-972.	2.1	14
152	Cellular aspartyl proteases promote the unconventional secretion of biologically active HIV-1 matrix protein p17. Scientific Reports, 2016, 6, 38027.	3.3	14
153	Defining the Native Disulfide Topology in the Somatomedin B Domain of Human Vitronectin. Journal of Biological Chemistry, 2007, 282, 5318-5326.	3.4	13
154	Human intelectin-1 (ITLN1) genetic variation and intestinal expression. Scientific Reports, 2021, 11, 12889.	3.3	13
155	Testing of the Additivity-Based Protein Sequence to Reactivity Algorithmâ€. Biochemistry, 2003, 42, 6460-6466.	2.5	12
156	Structure of the scorpion toxin BmBKTtx1 solved from single wavelength anomalous scattering of sulfur. Journal of Structural Biology, 2004, 145, 289-294.	2.8	12
157	A novel short-chain peptide BmKX from the chinese scorpion Buthus martensi karsch, sequencing, gene cloning and structure determination. Toxicon, 2005, 45, 309-319.	1.6	12
158	Total chemical synthesis of human Tâ€cell leukemia virus type 1 protease via native chemical ligation. Biopolymers, 2010, 94, 487-494.	2.4	12
159	Human Beta-Defensin 2 and 3 Inhibit HIV-1 Replication in Macrophages. Frontiers in Cellular and Infection Microbiology, 2021, 11, 535352.	3.9	12
160	Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search. RSC Advances, 2017, 7, 9989-9997.	3.6	11
161	Crystal structure of master biofilm regulator CsgD regulatory domain reveals an atypical receiver domain. Protein Science, 2017, 26, 2073-2082.	7.6	11
162	Systematic mutational analysis of human neutrophil Î±-defensin HNP4. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 835-844.	2.6	11

#	Article	IF	Citations
163	The first semi-synthetic serine protease made by native chemical ligation. Protein Expression and Purification, 2003, 29, 185-192.	1.3	10
164	Antimicrobial peptides. Seminars in Cell and Developmental Biology, 2019, 88, 105-106.	5.0	10
165	Thermodynamic instability of viral proteins is a pathogen-associated molecular pattern targeted by human defensins. Scientific Reports, 2016, 6, 32499.	3.3	10
166	Co-Encapsulating the Fusogenic Peptide INF7 and Molecular Imaging Probes in Liposomes Increases Intracellular Signal and Probe Retention. PLoS ONE, 2015, 10, e0120982.	2.5	10
167	Mutations that mimic phosphorylation of the HIVâ€1 matrix protein do not perturb the myristyl switch. Protein Science, 2007, 16, 1793-1797.	7.6	8
168	<scp>D</scp>â€Peptideâ€Based Drug Discovery Aided by Chemical Protein Synthesis. Israel Journal of Chemistry, 2011, 51, 868-875.	2.3	8
169	Total chemical synthesis of dengue 2 virus capsid protein via native chemical ligation: Role of the conserved salt-bridge. Bioorganic and Medicinal Chemistry, 2013, 21, 3443-3449.	3.0	8
170	Critical determinants of human neutrophil peptide 1 for enhancing host epithelial adhesion ofShigella flexneri. Cellular Microbiology, 2019, 21, e13069.	2.1	8
171	Defensins versus pathogens: an unfolding story. Oncotarget, 2015, 6, 28533-28534.	1.8	7
172	Key Determinants of Human Î±-Defensin 5 and 6 for Enhancement of HIV Infectivity. Viruses, 2017, 9, 244.	3.3	6
173	Mechanism through Which Retrocyclin Targets Flavivirus Multiplication. Journal of Virology, 2021, 95, e0056021.	3.4	6
174	Differential Susceptibility of Bacteria to Mouse Paneth Cell a-Defensins under Anaerobic Conditions. Antibiotics, 2014, 3, 493-508.	3.7	5
175	Reexamination of the recognition preference of the specificity pocket of the Abl SH3 domain. Journal of Molecular Recognition, 2003, 16, 131-138.	2.1	4
176	Total chemical synthesis of human interferon alphaâ€2b via native chemical ligation. Journal of Peptide Science, 2015, 21, 554-560.	1.4	4
177	Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2021366118.	7.1	4
178	Functional evolution within a protein superfamily. Proteins: Structure, Function and Bioinformatics, 2006, 63, 697-708.	2.6	2
179	Crystallization and preliminary X-ray studies of thymus and activation-regulated chemokine (TARC). Acta Crystallographica Section D: Biological Crystallography, 2003, 59, 163-165.	2.5	1
180	Additivityâ€based design of the strongest possible turkey ovomucoid third domain inhibitors for porcine pancreatic elastase (PPE) and Streptomyces griseus protease B (SGPB). FEBS Letters, 2013, 587, 3021-3026.	2.8	1

#	Article	IF	Citations
181	Design of peptide inhibitors for furin based on the C-terminal fragment of histone H1.2. Acta Biochimica Et Biophysica Sinica, 2008, 40, 848-854.	2.0	0